Clinical Trial

Multidimensional Burden of Platinum Resistant Ovarian Cancer (PROC) on Patients and Caregivers in Canada

Terminated
View on ClinicalTrials.gov →
Why the trial stopped
Recruitment
Summary
Filling the gap in Canadian evidence on the burden of PROC on QoL is essential. It will help better understand the impact of PROC on multiple aspects of the lives of patients and their caregivers and the real-life hurdles faced by PROC patients and their caregivers. The outputs of this study will help better understand the hurdles and challenges they face and the significant unmet medical need.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-06-16; most recent amendment 2026-04-01.
Status change: Enrolling by Invitation → Terminated 2026-04-01
Trial Details
NCT Number NCT07035067
Lead Sponsor PeriPharm
Conditions Ovarian Cancer, Caregiver Burden, Patient Burden
Enrollment 24 participants
Start Date 2025-07-15
Primary Completion 2026-04-01 (estimated)
Study Completion 2026-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-07